The lnc<scp>RNA MALAT</scp>1 functions as a competing endogenous <scp>RNA</scp> to regulate <scp>MCL</scp>‐1 expression by sponging miR‐363‐3p in gallbladder cancer

Shou-hua Wang, Wenjie Zhang, Xiaocai Wu, Mingzhe Weng, Ming-di Zhang, Qiang Cai, Di Zhou, Jiandong Wang, Zhiwei QuanJournal of Cellular and Molecular Medicine 2016 · DOI

TL;DR

This paper reveals that the long non-coding RNA MALAT1 acts as a "sponge" for microRNA-363-3p in gallbladder cancer (GBC). By sequestering miR-363-3p, MALAT1 leads to increased expression of MCL-1, a protein that promotes cancer cell survival and proliferation. This discovery identifies a novel therapeutic target for GBC, suggesting that inhibiting MALAT1 could be a promising treatment strategy.

What Problem Does This Paper Address?

Gallbladder carcinoma (GBC) is a challenging cancer with limited treatment options and a poor prognosis, especially in advanced stages. While the role of long non-coding RNAs (lncRNAs) in cancer is increasingly recognized, the specific mechanisms by which they contribute to GBC progression are not fully understood. This study aims to elucidate the role of MALAT1, a lncRNA previously implicated in other cancers, in GBC and to uncover the molecular pathways it influences. Specifically, the researchers investigate how MALAT1 might regulate key cancer-promoting genes and whether it could serve as a therapeutic target.

Methods

The researchers employed a multi-pronged approach to investigate the MALAT1-miR-363-3p-MCL-1 axis:

  • Quantitative Real-Time PCR (qRT-PCR): Used to measure the expression levels of MALAT1 and miR-363-3p in both GBC tissues and cell lines, as well as MCL-1 mRNA.
  • Western Blot Analysis: Employed to assess the protein levels of MCL-1.
  • Luciferase Reporter Assays: Utilized to confirm the direct interaction between MALAT1 and miR-363-3p by examining the effect of miR-363-3p on the luciferase activity of constructs containing wild-type or mutated MALAT1 binding sites.
  • RNA Immunoprecipitation (RIP) Assays: Performed to determine if MALAT1 and miR-363-3p are present within the same RNA-induced silencing complex (RISC), specifically by looking for MALAT1 enrichment in Ago2 immunoprecipitates.
  • Biotin-Labeled miRNA Pull-Down Assays: Used to directly demonstrate the binding of miR-363-3p to MALAT1.
  • RNA Interference (RNAi) and Transfection: Employed to silence MALAT1 (using siRNAs and shRNAs) and to manipulate miR-363-3p levels (using mimics and inhibitors) in GBC cell lines.
  • Cell Proliferation Assays (CCK-8): Assessed the impact of MALAT1 and miR-363-3p manipulation on GBC cell growth.
  • Flow Cytometric Analysis: Used to analyze the cell cycle distribution (specifically the S-phase population) and apoptosis rates in response to experimental manipulations.
  • Xenograft Mouse Model: Used to evaluate the in vivo effects of MALAT1 knockdown on tumor growth and MCL-1 expression.

Datasets

The study utilized:

  • Human Gallbladder Cancer Tissues: 33 pairs of GBC tissues and matched adjacent normal gallbladder tissues were collected from patients who underwent surgery.
  • Gallbladder Cancer Cell Lines: SGC-996 and NOZ cell lines were used for in vitro experiments.
  • Human Intrahepatic Biliary Epithelial Cell Line: H69 was used as a non-tumorigenic control.

No new benchmarks were introduced; standard cell lines and patient-derived tissues were used.

Key Insights and Ideas

  • MALAT1 as an Oncogene in GBC: The study provides strong evidence that MALAT1 is not just present but actively contributes to GBC progression, being significantly upregulated in tumor tissues and driving proliferation.
  • The ceRNA Mechanism: The paper clearly demonstrates MALAT1's role as a competing endogenous RNA (ceRNA), a crucial concept in understanding how lncRNAs regulate gene expression by "sponging" microRNAs.
  • miR-363-3p as a Tumor Suppressor: Conversely, miR-363-3p appears to act as a tumor suppressor in GBC, as its levels are decreased in tumors, and its restoration (or MALAT1 knockdown) inhibits cancer growth.
  • MCL-1 as a Key Downstream Target: The identification of MCL-1 as a direct target of miR-363-3p, and thus indirectly regulated by MALAT1, is critical. MCL-1's known anti-apoptotic function makes it a significant player in cancer cell survival.
  • Therapeutic Potential: The findings strongly suggest that targeting MALAT1 could be a viable therapeutic strategy, offering a new avenue for treating GBC.

Key Results

  • MALAT1 Overexpression: MALAT1 expression was significantly higher in GBC tissues compared to normal tissues (P < 0.05).
  • miR-363-3p Downregulation: miR-363-3p was downregulated in GBC tissues, and its expression showed a significant negative correlation with MALAT1 levels (R = -0.544, P < 0.01).
  • MALAT1-miR-363-3p Interaction: Luciferase assays and pull-down assays confirmed that MALAT1 directly binds to miR-363-3p.
  • MCL-1 Regulation: Knockdown of MALAT1 led to decreased MCL-1 mRNA and protein levels, which was reversed by inhibiting miR-363-3p, confirming MALAT1's role as a ceRNA for miR-363-3p to regulate MCL-1.
  • In Vitro Effects: Silencing MALAT1 in GBC cells reduced proliferation, decreased the S-phase cell population, and induced apoptosis. These effects were partially reversed by co-transfecting with a miR-363-3p inhibitor.
  • In Vivo Effects: In a xenograft mouse model, MALAT1 knockdown significantly reduced tumor volume and decreased MCL-1 protein levels in tumor tissues.

Limitations and Future Work

  • Cohort Size: The authors acknowledge that a larger cohort of gallbladder cancer patients is needed to confirm the prognostic value of MALAT1.
  • In Vivo miR-363-3p Levels: While MALAT1 knockdown reduced tumor volume and MCL-1 levels in vivo, the paper notes that miR-363-3p levels were also decreased in tumor tissues from the MALAT1-silenced group. Further investigation into the precise in vivo dynamics of this interaction would be beneficial.
  • Broader Impact: While the study focuses on the MALAT1/miR-363-3p/MCL-1 axis, it would be valuable to explore if MALAT1 influences other pathways or targets in GBC.
  • Clinical Translation: The paper suggests that targeting the ceRNA regulatory network may be a novel therapeutic strategy. Future work would involve developing and testing specific MALAT1 inhibitors in preclinical and clinical settings.

Summary updated

Abstract

Gallbladder carcinoma (GBC) is an aggressive neoplasm, and the treatment options for advanced GBC are limited. Recently, long non-coding RNAs (lncRNAs) have emerged as new gene regulators and prognostic markers in several cancers. In this study, we found that metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) expression was up-regulated in GBC tissues (P < 0.05). Luciferase reporter assays and RNA pull down assays showed that MALAT1 is a target of miR-363-3p. Real-time quantitative PCR and Western blot analysis indicated that MALAT1 regulated Myeloid cell leukaemia-1 (MCL-1) expression as a competing endogenous RNA (ceRNA) for miR-363-3p in GBC cells. Furthermore, MALAT1 silencing decreased GBC cell proliferation and the S phase cell population and induced apoptosis in vitro. In vivo, tumour volumes were significantly decreased in the MALAT1 silencing group compared with those in the control group. These data demonstrated that the MALAT1/miR-363-3p/MCL-1 regulatory pathway controls the progression of GBC. Inhibition of MALAT1 expression may be to a novel therapeutic strategy for gallbladder cancer.
BibTeX
@article{wang2016lnc,
  author = {Shou-hua Wang and Wenjie Zhang and Xiaocai Wu and Mingzhe Weng and Ming-di Zhang and Qiang Cai and Di Zhou and Jiandong Wang and Zhiwei Quan},
  title = {{The lnc<scp>RNA MALAT</scp>1 functions as a competing endogenous <scp>RNA</scp> to regulate <scp>MCL</scp>‐1 expression by sponging miR‐363‐3p in gallbladder cancer}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2016},
  doi = {10.1111/jcmm.12920},
}
Figure